Advisory

Learn MoreFREE TRIAL

{NAS.ISRG} is a dominant leader in the robotic-assisted surgery market, known for its da Vinci surgical systems.

Earnings Alert: Q1 2026

• Release Date: Tomorrow, April 21, 2026, after market close.
• Estimates: Analysts expect EPS of approximately $2.08 – $2.16 on revenue of $2.61 – $2.67 billion.

Key Focus: Investors will be watching for updates on the rollout of the da Vinci 5* and commentary on 2026 procedure growth guidance (currently 13–15%).

Fundamental Metrics

• Market Cap: ~$166.65 Billion.
• Valuation:

* Forward P/E: 41.06x
* Trailing P/E: 59.54x
* Price-to-Book: 9.35x

• Analyst Sentiment: Rated as a Buy (Average Rating: 1.9) with a median price target generally cited near $600, implying significant potential upside from current levels.

Recent Developments & Catalysts
FDA Expansions: In early 2026, the company received FDA clearance for the da Vinci 5for select cardiac procedures and recently expanded da Vinci SP* indications to include inguinal hernia and appendectomy.

• Operational Milestone: The company reached a milestone of 20 million procedures performed globally in January 2026, reinforcing its massive “razor-and-blade” recurring revenue model (instruments and accessories).
• Guidance Caution: The stock has seen some pressure in early 2026 due to conservative procedure growth guidance (13-15% vs. 18% in 2025), as the company laps tough year-over-year comparisons.

Performance Context

• 52-Week Range: $427.84 – $603.88.
• Technical Trend: The stock is currently trading below its 200-day moving average ($503.09), suggesting it is in a period of consolidation or correction ahead of its earnings results. It has underperformed the broader S&P 500 YTD by approximately 18%.

Actionable Insight: ISRG remains a high-quality growth play, but current valuation multiples reflect high expectations. Tomorrow’s earnings call will be critical to determine if the 2026 growth deceleration is fully priced in.